ReviewTheranostics2026
Translational Models for Glioblastoma: Revolutionizing Drug Development and Personalized Medicine through Clinical Insights.
Review in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Human Blood-Brain Tumor Barrier on a Chip to Investigate Personalized Treatment for Glioblastoma Patients.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Organoids to Model Tumor Microenvironment in Progression of Pathogenesis and Treatment Resistance in Glioblastoma Multiforme.Brain sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) remains one of the most aggressive and treatment resistant brain tumors and continues to present major challenges for effective therapeutic development. The failure of numerous late-stage clinical trials highlights the limited predictive value of conventional preclinical models. Although established cell lines, two-dimensional cultures, and animal models have been extensively employed, existing platforms fail to adequately recapitulate the complex tumor microenvironment, blood brain barrier function, and interpatient heterogeneity that drive therapeutic resistance in GBM. To address this translational limitation, advanced experimental systems have been developed to more accurately reproduce key features of the human GBM microenvironment through the integration of microengineering approaches, biomaterials, and patient derived cells. This review focuses on recent advances in microfluidic GBM chip models and three-dimensional bioprinted GBM platforms, while also summarizing a broad range of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.